Projects of the Faculty of Pharmacy and Biochemistry
Novel bioanalytical solutions in personalized breast cancer treatment
| Status | Finished |
|---|---|
| Acronym | OncoBioAnalytics |
| Summary | Breast cancer is the most common malignant tumor in women with a one in eight prevalence. Almost 80% of breast cancers are hormone receptor positive (HR+) and treated with endocrine therapy. Recently, a combination of endocrine (aromatase inhibitors anastrozole or letrozole; antiestrogen fulvestrant) and targeted therapy (CDK4/6 inhibitors palbociclib and ribociclib) has been introduced for the treatment of metastatic breast cancer subtype HR+, HER2- (human epidermal growth factor receptor 2). To achieve better therapy outcomes and reduce adverse drug events, a personalized approach to breast cancer treatment in routine clinical practice is needed. Reliable and accurate analytical methods for therapeutic drug monitoring (TDM) of oncology drugs can significantly contribute to this goal. The aim of this study is to propose new, reliable, sensitive and selective bioanalytical tools that will serve as a platform for a personalized approach to breast cancer treatment. Emphasis will be given to newly approved palbociclib and ribociclib, which are co-administered with aromatase inhibitors or fulvestrant. Pharmacokinetic and metabolic studies will also be conducted. Proposed new analytical methods will be used to monitor plasma concentrations of selected drugs. Highly sophisticated liquid chromatography coupled to mass spectrometry methods (HPLC-MS) will be developed. As an alternative to expensive and complex HPLC-MS technique, robust and fully automated capillary electrophoresis (CE) technique will be developed. CE has a great potential for translation to clinical setting due to minimal training and supervision required after establishing validated protocols. Research results will enable optimal therapeutic dosing and enhance the effectiveness of anticancer therapy, avoiding toxicity, concentration-dependent side-effects or therapeutic failure. This project will contribute to implementation of TDM for targeted breast cancer therapy as a part of standard health care. |
| Line of financing |
Croatian Science Foundation |
| Duration | 01.03.2020. - 28.02.2025. |
| Budget amount | 250.580,66 EUR |
| Lead | - |
| Results |
|